Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Post-polycythemia Vera Myelofibrosis(Post-PV MF)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Ended earlyNCT03755518
What this trial is testing

A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

Who this might be right for
Primary MyelofibrosisPost-Polycythemia Vera MyelofibrosisMyelofibrosis+1 more
Celgene 38
Large-scale testing (Phase 3)Ended earlyNCT02055781
What this trial is testing

Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia

Who this might be right for
Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
CTI BioPharma 311
Large-scale testing (Phase 3)Study completedNCT00952289
What this trial is testing

COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

Who this might be right for
MPN (Myeloproliferative Neoplasms)
Incyte Corporation 309
Testing effectiveness (Phase 2)Study completedNCT02124746
What this trial is testing

Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia

Who this might be right for
Primary MyelofibrosisPost-Polycythemia Vera MyelofibrosisPost-Essential Thrombocythemia Myelofibrosis+2 more
Sierra Oncology LLC - a GSK company 87
Testing effectiveness (Phase 2)Study completedNCT04218071
What this trial is testing

Actuate 1901: 9-ING-41 in Myelofibrosis

Who this might be right for
Myelofibrosis
Actuate Therapeutics Inc. 17
Large-scale testing (Phase 3)Study completedNCT00934544
What this trial is testing

Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial

Who this might be right for
Myelofibrosis
Novartis Pharmaceuticals 219
Testing effectiveness (Phase 2)Study completedNCT03136185
What this trial is testing

Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)

Who this might be right for
MyelofibrosisPost-polycythemia Vera Myelofibrosis (PPV-MF)Post-essential Thrombocythemia Myelofibrosis (PET-MF)+1 more
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) 90
Large-scale testing (Phase 3)Study completedNCT03952039
What this trial is testing

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

Who this might be right for
Primary MyelofibrosisPost-Polycythemia VeraMyelofibrosis
Celgene 202
Testing effectiveness (Phase 2)Study completedNCT01644110
What this trial is testing

Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF

Who this might be right for
Primary MyelofibrosisSecondary MyelofibrosisPMF+3 more
University of Ulm 96
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07750574
What this trial is testing

Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis

Who this might be right for
MyelofibrosisMyelofibrosis Due to and Following Polycythemia VeraMyelofibrosis Transformation in Essential Thrombocythemia+9 more
Chengdu Zenitar Biomedical Technology Co., Ltd 105
Early research (Phase 1)UnknownNCT05279001
What this trial is testing

A Safety and Tolerability Study of Jaktinib

Who this might be right for
Myelofibrosis
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 26
Large-scale testing (Phase 3)Looking for participantsNCT07357727
What this trial is testing

Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

Who this might be right for
Primary Myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis (PPV-MF)Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Novartis Pharmaceuticals 460
Testing effectiveness (Phase 2)Looking for participantsNCT05280509
What this trial is testing

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

Who this might be right for
MyelofibrosisPrimary MyelofibrosisPost-PV MF+1 more
Telios Pharma, Inc. 70
Large-scale testing (Phase 3)Study completedNCT01178281
What this trial is testing

Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence

Who this might be right for
Primary MyelofibrosisMPN-associated Myelofibrosis
Celgene 267
Early research (Phase 1)Looking for participantsNCT06343805
What this trial is testing

LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

Who this might be right for
Primary Myelofibrosis
Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company 256
Testing effectiveness (Phase 2)Ended earlyNCT01668173
What this trial is testing

HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET

Who this might be right for
Myeloproliferative Neoplasms
Memorial Sloan Kettering Cancer Center 7
Testing effectiveness (Phase 2)Study completedNCT02098161
What this trial is testing

LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

Who this might be right for
Polycythemia Vera, Post-Polycythemic Myelofibrosis PhasePrimary MyelofibrosisSecondary Myelofibrosis
M.D. Anderson Cancer Center 50
Testing effectiveness (Phase 2)Study completedNCT01445769
What this trial is testing

Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis

Who this might be right for
Primary MyelofibrosisPost-Polycythemia Vera MyelofibrosisPost-Essential Thrombocythemia Myelofibrosis
Incyte Corporation 45
Testing effectiveness (Phase 2)Study completedNCT01200498
What this trial is testing

Study of SB939 in Subjects With Myelofibrosis

Who this might be right for
Myeloproliferative Disorders
M.D. Anderson Cancer Center 23
Testing effectiveness (Phase 2)Study completedNCT01787552
What this trial is testing

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Who this might be right for
Primary MyelofibrosisThrombocytosisEssential Thrombocythemia+7 more
Novartis Pharmaceuticals 50
Next Page